Novo Nordisk Introduces Wegovy Subscription Program

Novo Nordisk has launched the first multi-month subscription program for its FDA-approved medication, Wegovy®. This new option provides eligible self-pay patients with predictable pricing and potential savings of up to $1,200 per year. Available through partners like Ro starting March 31, 2026, the program aims to improve access and adherence for individuals using Wegovy® for weight management. This initiative represents a significant step in making chronic treatments more affordable and manageable for a broader patient population.